阿法骨化醇联合碳酸钙D_3治疗老年骨质疏松的临床疗效研究

Clinical efficacy of alfacalcidol combined with calcium carbonate D3in the treatment of elderly osteoporosis

目的探讨阿法骨化醇联合碳酸钙D3治疗老年骨质疏松的临床疗效。方法选取2015年1月—2016年1月九江市第一人民医院收治的老年骨质疏松患者78例,按照入院先后顺序将患者分为对照组与治疗组,各39例。对照组给予碳酸钙D3治疗,治疗组给予阿法骨化醇联合碳酸钙D3治疗,两组患者均治疗1个月,比较两组患者治疗后骨痛症状改善效果、治疗前后L2L4及股骨颈骨密度（MBD）值、药物不良反应发生情况。结果治疗组患者骨痛症状改善率高于对照组,差异有统计学意义（P<0.05）。治疗前两组患者L2L4及股骨颈BMD值比较,差异无统计学意义（P>0.05）;治疗后治疗组L2L4及股骨颈BMD值高于治疗前,且高于对照组,差异有统计学意义（P<0.05）。两组患者不良反应发生率比较,差异无统计学意义（P>0.05）。结论阿法骨化醇联合碳酸钙D3治疗老年骨质疏松的临床疗效确切,可有效改善患者BMD,且安全性高。

Objective To evaluate the clinical efficacy of alfacalcidol combined with calcium carbonate D_3 in the treatment of elderly osteoporosis. Methods A total of 78 elderly osteoporosis patients from January 2015 to January 2016 in the First People's Hospital of Jiujiang City were selected,which were divided into control group and treatment group by order of admission,39 cases in each. The control group was treated with calcium carbonate D_3,treatment group was treated with alfacalcidol combined with calcium carbonate D_3,after one months of treatment in both groups,effect of bone pain symptoms improving,bone mineral density( BMD) of L_2- L_4 and femoral neck,occurrence of adverse reactions between the two groups were compared. Results Bone pain symptoms improving rate of treatment group was higher than control group( P < 0. 05). Before treatment BMD of L_2- L_4 and femoral neck between the two groups showed no significant differences( P > 0. 05); after treatment BMD of L_2- L_4 and femoral neck of the treatment group was higher than before treatment and control group( P < 0. 05).Adverse reactions rate between the two groups showed no significant differences( P > 0. 05). Conclusion Alfacalcidol combined with calcium carbonate D3 in the treatment of elderly osteoporosis have significant effect,and effectively improving BMD,and have high sefety.